FDA Drug information
Vivelle-Dot
Up to date, easily accessible information about drugs approved by the US Food & Drug Administration (FDA)
- Vivelle-Dot ESTRADIOL .025 mg/d Novartis Pharmaceuticals Corporation
- Vivelle-Dot ESTRADIOL .025 mg/d Sandoz Inc
- Vivelle-Dot ESTRADIOL .0375 mg/d Novartis Pharmaceuticals Corporation
- Vivelle-Dot ESTRADIOL .0375 mg/d Sandoz Inc
- Vivelle-Dot ESTRADIOL .05 mg/d Novartis Pharmaceuticals Corporation
- Vivelle-Dot ESTRADIOL .05 mg/d Sandoz Inc
- Vivelle-Dot ESTRADIOL .075 mg/d Novartis Pharmaceuticals Corporation
- Vivelle-Dot ESTRADIOL .075 mg/d Sandoz Inc
- Vivelle-Dot ESTRADIOL .1 mg/d Novartis Pharmaceuticals Corporation
- Vivelle-Dot ESTRADIOL .1 mg/d Sandoz Inc
Learning Zones
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.